



- Global Research Centre of Excellence and Anti counterfeit technology launched by Dr. APJ Abdul Kalam and Dr. John LaMattina, President, Research & Development, Pfizer Inc.
- Asia's first state-of-art flexo technology facility for aluminium lid printing inaugurated by Principal Scientific Adviser, Govt. of India, Dr. R. Chidambaram
- Research Academy Centre at Bangalore inaugurated by Additional Chief Secretary Health & Family Welfare, Mrs. Usha Ganesh
- Launch of Singapore Chapter of ACRP by Executive Director, Economic Development Board, Govt. of Singapore, Mr. Yeoh Keat Chuan
- The Controller of Patents, Govt of India, upheld Bilcare's patent on metalized packaging films
- Bilcare Singapore Pte Ltd bought Singular ID Pte Ltd, the provider of integrated high technology enterprise brand security system, for a consideration of Singapore \$ 19.58 million.

- DMF regd. with USFDA
- EEC / USP
- Member, IQA, London
- OPPI Award Winner
- Pioneer Status from Govt. of Singapore
- ISO 9001:2000 & 14001:2004 Company

Bilcare, an unique organization with a strong research foundation and an unending quest for global leadership. An organization, integrated with global Pharmaceuticals having best in class manufacturing and research facilities spread worldwide. An organization made up of motivated people who go that extra mile to spread excellence and joy.

INDIA : USA : SINGAPORE : GERMANY : BRAZIL : CHINA : UK

Bilcare Limited - Regd. Office : 1028, Shirol, Pune 410 505.

Unaudited Financial Results for the quarter and nine months ended 31st December, 2007

(Rs. in Crores)

Sr. No.	Particulars	Three months ended 31/12/2007 (Unaudited)	Corresponding Three months ended 31/12/2006 (Unaudited)	Nine months ended 31/12/2007 (Unaudited)	Corresponding Nine months ended 31/12/2006 (Unaudited)	Previous Year ended 31/03/2007 (Audited)	Consolidated Three months ended 31/12/2007 (Unaudited)	Consolidated Nine months ended 31/12/2007 (Unaudited)	Consolidated Previous Year ended 31/03/2007 (Audited)
1.	Net Sales/Income from Operations	104.12	83.47	294.95	234.35	322.98	149.29	417.91	407.86
2.	Other Income	3.32	3.60	8.47	4.45	18.46	3.43	9.39	17.87
3.	Total Income (1+2)	107.44	87.07	303.42	238.80	341.44	152.72	427.30	425.73
4.	Expenditure								
a.	(Increase) / Decrease in Stock in Trade and Work in progress	1.86	(0.30)	(11.19)	(1.31)	(1.95)	1.96	(11.37)	(5.15)
b.	Consumption of Raw Materials	60.77	51.63	187.02	146.81	198.92	80.00	242.16	248.39
c.	Employee Cost	4.02	3.68	11.71	8.76	12.00	15.42	44.07	22.39
d.	Depreciation	3.72	2.78	10.82	7.19	10.72	5.45	15.25	15.44
e.	Other Expenditure	9.14	5.68	26.37	15.78	23.98	14.78	43.82	43.11
f.	Total	79.51	63.47	224.73	177.23	243.67	117.61	333.93	324.18
5.	Interest	2.80	2.05	8.29	5.35	7.96	3.08	9.17	9.12
6.	Profit before Tax (3) - (4+5)	25.13	21.55	70.40	56.22	89.81	32.02	84.20	92.43
7.	Tax Expense	8.54	7.35	23.93	19.08	31.25	9.41	25.98	32.51
8.	Net Profit after Tax (6-7)	16.59	14.20	46.47	37.14	58.56	22.62	58.22	59.92
9.	Paid-up Equity Share Capital (face value Rs.10/- each)	16.45	14.20	16.45	14.20	14.20			
10.	Reserves excluding Revaluation Reserves					184.33			189.70
11.	Earnings Per Share for the Period (Rs.)								
a.	Basic	10.08	10.00	28.24	26.15	41.24			
b.	Diluted	8.64	9.36	24.21	24.56	35.29			
12.	Public Shareholding								
-	No. of Shares	9126791	7619526	9126791	7619526	7619526			
-	Percentage of Shareholding	55.47%	53.66%	55.47%	53.66%	53.66%			

Notes :

1. The Company's main business segment is pharma packaging research solutions.
2. The Company had received 3 investor complaints during the quarter, which were redressed and there were no investor complaints pending for redressal at the commencement and at the end of the quarter.
3. The Company has, during the quarter allotted - 458,361 Equity Shares of Rs. 10/- each at a conversion price of Rs. 880 per share, including premium, upon partial conversion of the Foreign Currency Convertible Bonds issued earlier and 745,000 Equity Shares of Rs. 10/- each at Rs. 535 per share, including premium, upon conversion of Warrant 'A' issued to the promoters.
4. During the quarter, the Company's subsidiary in Singapore has acquired Singular ID Pte Ltd., a Company at Singapore.
5. The previous year's figures have been regrouped / readjusted wherever necessary.
6. The above unaudited Financial Results were approved by the Board of Directors of the Company at its meeting held on 29th January, 2008.
7. The Company has started providing Consolidated results from the current year and hence figures for the corresponding period of the previous year are not available.

For Bilcare Limited

Mohan H. Bhandari
Managing Director

Pune : 29th January, 2008

Size : 33 cms X 21cms